A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will

Trial Details

NCT ID
NCT04928846
Phase
PHASE3
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Telisotuzumab Vedotin
  • Docetaxel
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Duarte, California, United States|34.13945,-117.97729
  • Lancaster, California, United States|34.69804,-118.13674
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Projected life expectancy of at least 12 weeks.
  • Participants must have c-Met overexpressing non-small cell lung cancer (NSCLC) as assessed by an AbbVie designated immunohistochemistry (IHC) labor…
  • Archival or fresh tumor material must be submitted for assessment of c-Met protein expression levels during the Pre-Screening period. Tumor materia…
  • If a participant was prescreened for Study M14-239 but did not enroll, tumor material previously submitted for Study M14-239 may be used for Study …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →